# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the pric...
Stephens & Co. analyst George Sellers reiterates Anika Therapeutics (NASDAQ:ANIK) with a Equal-Weight and maintains $22 ...
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.05 per share which beat the analyst consensus estimate of $(...
Fiscal 2024 GuidanceIn 2024, Anika is prioritizing accelerated growth in profitability, with a focus on the products with the g...
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and raises the pric...
Integrity marks Anika's entrance into the fast-growing $150 million+2 U.S. rotator cuff augmentation market and expansion o...